Backgrounds: Rennin angiotensin aldosterone system (RAS) plays a crucial role in the initiation and development of cardiac remodeling. Despite great success with traditional therapy, such as angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor 1 (AT1) antagonists, there are still many patients with poorly controlled high blood pressure and target organs dysfunction due to many inherent disadvantages including compliance, side effects, and lack of complete reversal of pathophysiologica...